MetaCap

Zymeworks Inc. Company Profile

NASDAQ: ZYMEHealth CareBiotechnology: Pharmaceutical PreparationsUSD

26.14-0.72 (-2.68%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Zymeworks at a glance

Zymeworks Inc. (NASDAQ: ZYME) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Middletown, DE. Zymeworks is led by Mr. Kenneth H. Galbraith C.A. and employs about 279 people. At a market capitalization of $1.81 billion, it is considered a small-cap company.

Its SEC Central Index Key (CIK) is 0001937653, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Zymeworks do?

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

Business description based on the company's public filings.

Company information

Legal name
Zymeworks Inc.
Ticker
NASDAQ: ZYME
Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Kenneth H. Galbraith C.A.
Employees
279
Headquarters
108 Patriot Drive, Middletown, DE, United States
Phone
302 274 8744
SEC CIK
0001937653
Latest annual report
10-K · Mar 2, 2026

Companies similar to Zymeworks

ZYME peer companies
CompanyPrice% ChgMarket capCompare
MRVIMaravai LifeSciences Holdings Inc. Class A6.98-2.92%$1.81Bvs ZYME
SEPNSepterna Inc.38.61-1.51%$1.84Bvs ZYME
VERAVera Therapeutics Inc. Class A25.45-4.86%$1.84Bvs ZYME
IMNMImmunome Inc.15.69-5.54%$1.85Bvs ZYME
ETONEton Pharmaceuticals Inc.60.85-0.83%$1.76Bvs ZYME
STOKStoke Therapeutics Inc.26.81-0.45%$1.75Bvs ZYME
TRAXFirst Tracks Biotherapeutics Inc.41.64-6.34%$1.75Bvs ZYME
BHVNBiohaven Ltd.12.39-9.23%$1.87Bvs ZYME

Related